Ritanserin in relapse prevention in abstinent alcoholics: Results from a placebo-controlled double-blind international multicenter trial

Alcoholism: Clinical and Experimental Research

Volumn 23, Issue 2, 1999, Pages 230-235

  Wiesbeck, Gerhard A ^b   Weijers, H G ^c   Chick, J ^a   Naranjo, C A ^c   Boening, J ^c   Beckmann, H ^c  

^a Alcohol Problems Clinic   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NONE

Author keywords

Alcoholism; Craving; Relapse Prevention; Ritanserin

Indexed keywords

ALCOHOL; PLACEBO; RITANSERIN; SEROTONIN 2 ANTAGONIST;

ABSTINENCE; ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 0033061442     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1999.tb04105.x     Document Type: Article

References (29)

1. Bech P, Rasmussen S, Dahl A, Lauritsen B: The Withdrawal Syndrome Scale for alcohol and related psychoactive drugs: Interobserver reliability and construct validity. Nordisk Psykiatrisk Tidsskrift 43:291-294, 1989
2. Buydens-Branchey L, Branchey MH, Noumair D: Age of alcoholism onset. I. Relationship to psychopathology. Arch Gen Psychiatry 46: 225-230, 1989
3. Cornish J, Johnson B: A double-blind, placebo-controlled evaluation of ritanserin in the treatment of cocaine abuse. Janssen Research Found Clin Res Rept 36, 1995
4. 2 antagonist ritanserin. Curr Therap Res 41:427-432, 1987
5. Favre JD, Guelfi-Sozzi C, Delalleau B, Loo H: Tianeptine and alcohol dependence. Eur Neuropsychopharmacol 7(suppl 3):347-351, 1997
6. Grebb JA, Clyde C, Schafer JW: Ritanserin in the treatment of alcohol dependence. Janssen Res Found Clin Res Rept 40, 1995
7. Irwin M, Baird S, Smith TL, Schuckit M: Use of laboratory tests to monitor heavy drinking by alcoholic men discharged from a treatment program. Am J Psychiatry 145:595-599, 1988
8. Janssen Research Foundation: Ritanserin (R 55 667) Investigational New Drug Brochure 5th ed. Janssen Research Foundation, Beerse, Belgium, 1992
9. Kranzler HR, Burleson JA, Korner P: Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152:391-397, 1995
10. Lee E: Statistical Methods for Survival Data Analysis. Lifetime Learning Publishers, Behmont, California, 1980
11. LeMarquand D, Pihl RO, Benkelfat C: Serotonin and alcohol intake, abuse and dependence. Clinical evidence. Biol Psychiatry 36:326-337, 1994
12. Leysen JE, Gommeren W, Van Compel P, Wijnants J, Janssen PFM, Laduron PM: Receptor binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600-611, 1985
13. Meert TF, De Haes PLAJ, Vermote PCM, Janssen PAJ: A pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat. Drug Dev Res 19:353-373, 1990
14. Meert T, Awouters F, Niemegeers CJE, Schellekens KHL, Janssen PAJ: Ritanserin reduces abuse of alcohol, cocaine and fentanyl in rats. Pharmacopsychiatry 24:159-163, 1991
15. Meert TF, Janssen PJ: Ritanserin a new therapeutic approach for drug abuse. Part 1: Effects on alcohol. Drug Dev Res 24:235-249, 1991
16. Monti JM, Alterwain P: Ritanserin decreases alcohol intake in chronic alcoholics. Lancet 1:60, 1991
17. 2 antagonist, in heavy social drinkers: Desire to drink, alcohol intake and related effects. Addiction 90:893-905, 1995a
18. Naranjo CA, Bremner KE, Lanctot KL: Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 90:87-99, 1995b
19. Naranjo CA, Dongier M, Bremner KE: Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 92:969-978, 1997
20. Pangalila-Ratur Langi EA, Janssen AAI: Ritanserin in the treatment of generalized anxiety disorder. A placebo-controlled trial. Hum Psychopharmacol 3:207-212, 1988
21. Penick EC, Powell BJ, Nickel EJ, Read MR, Gabrielli WF, Liskow BI: Examination of Cloninger's type I and type II alcoholism with a sample of male alcoholics in treatment. Alcohol Clin Exp Res 14:623-629, 1990
22. Pettinati HM: Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcohol Clin Exp Res 20:23A-29A, 1996
23. 2 blockade on alcohol intake in rats selectively bred for high and low catecholamine responses to stress. Integr Physiol Behav Sci 26:189-199, 1991
24. Rawson R, Grebb JA, Clyde C, Schafer J: A double-blind, placebo-controlled evaluation of ritanserin in the treatment of cocaine abuse. Janssen Res Found Clin Res Rept 33, 1995
25. Reyntjens A, Gelders YG, Hoppenbrouwers MLJA, Vanden Bussche G: Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin S2 receptor blocker. Drug Dev Res 8:205-211, 1986
26. Roy A, DeJong J, Lamparski D, Adinoff B, George T, Moore V, Garnett D, Kerich M, Linnoila M: Mental disorders among alcoholics. Relationship to age of onset and cerebrospinal fluid neuropeptides. Arch Gen Psychiatry 48:423-427, 1991
27. Schuckit MA: Biological vulnerability to alcoholism. J Consult Clin Psychol 55:301-309, 1987
28. Sellers EM, Higgins CA, Tompkins DM, Romach MK: Serotonin and alcohol drinking, in Harris L (ed) Proceedings of the 53d Annual Scientific Meeting, the Committee on Problems of Drug Dependence. Inc. NIDA Research Monograph, Washington DC, US Government Printing Office, 119:141-145, 1992
29. Toneatto T, Sellers EM, Sobell LC, Sobell MB: Perception of whether drug or placebo had been administered as a determinant of drinking reduction, in Naranjo CA, Sellers EM (eds) Novel Pharmacological Interventions for Alcoholism, New York: Springer-Verlag, 1992, pp 161-183